Er-Kim has signed an agreement with Sentynl Therapeutics to distribute Nulibry and Zokinvy across 33 countries in Central and Eastern Europe, the Mediterranean region, and Eurasia. The collaboration aims to expand access to these rare disease therapies in markets where they were previously limited.

Nulibry, for injection, is the only EMA and FDA-approved therapy to reduce mortality risk in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare genetic disorder can cause severe neurological damage and often presents at birth, progressing rapidly and leading to premature death if untreated. Zokinvy is the sole approved therapy for Hutchinson-Gilford Progeria Syndrome (HGPS) and certain Progeroid Laminopathies in patients aged 12 months and older with a minimum body surface area of 0.39 m². These conditions cause harmful protein buildup, accelerating aging and resulting in heart problems typically seen in older adults. Children with Progeria age eight to ten times faster than healthy peers.

Under the agreement, Er-Kim will manage distribution in countries including Poland, Greece, Turkey, Czechia, Romania, Kazakhstan, and Russia. Cem Zorlular, chief executive officer of Er-Kim, said: “Providing rare disease patients with timely access to life-altering medications is paramount, and we are proud to have consistently delivered treatments across a wide geographic area. We are therefore thrilled to collaborate with Sentynl to bring Nulibry and Zokinvy to patients in these designated regions, offering a vital chance at improved lives. Er-Kim’s global expertise in the distribution of rare disease treatments globally drives our mission to expand drug accessibility through strategic partnerships.”

Matt Heck, chief executive officer of Sentynl, added: “The work we do is centered around developing therapies that extend, improve, or enhance the lives of people with rare diseases. This partnership is an important milestone and enables us to bring Nulibry and Zokinvy to more patients around the world.”

Er-Kim was established in 1981 and has partnerships with over 40 global leaders, distributing more than 68 products to over 50 countries. The company employs over 300 professionals worldwide and generates annual revenues exceeding EUR 305 million. Sentynl Therapeutics is a US-based commercial-stage biopharmaceutical company focused on rare disease treatments and operates globally through its parent, Zydus Group, to advance development, manufacturing, and access.